Market Highlights
The global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period. Theranostics is a new field of medicine which combines therapeutics, nanoscience, and diagnostics based on specific targeted diagnostic tests. Theranostics is also called as theragnostics or companion diagnostics (CDx), or pharmacodiagnostics or personalized medical care, or personalized therapy, or personalized medicine technology. Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment. Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases. In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8057
Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules. Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.
Segmentation
The global theranostics market has been segmented into the therapeutic area, technology, end user, and region.
By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others. The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.
On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others. The sequencing segment is likely to register comparatively higher CAGR over the forecast period due to the increasing number of proof-of-concept case studies and research related to sequencing, particularly next-generation sequencing (NGS) technology.
Based on end user, the market has been classified into hospitals and clinics, diagnostic laboratories, and others.
Key Players
Few of the prominent players in the global theranostics market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc., Focus Diagnostics, Abbott Laboratories, Illumina, Inc., Agilent Technologies, Inc., QIAGEN, Myriad Genetics, Inc., Foundation Medicine, Inc., and AmeriPath, Inc.
Regional Analysis
The global theranostics market has been categorized on the basis of region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. On a regional basis, the Americas would command the market throughout the forecast period attributed to the domicile of major market participants, increasing research and development activities, and growing adoption of theranostics in the US and Canada. For instance, in June 2018, Genome Canada launched a national initiative for clinical implementation of precision health that would ultimately impact the market growth in the near future.
Europe would follow Americas in terms of value over the forecast period due to flourishing pharmaceutical and medical device companies, increasing partnerships and collaborations between life science companies and medical diagnostics companies, and growing personalized medicine sector. Personalized medicine (PM) is an emerging approach to prevention, diagnosis, treatment, and care which is assisting in addressing the challenge of the aging of the population, rising prevalence of chronic diseases, and increasing healthcare costs.
The market in Asia-Pacific would register the fastest market growth over next seven years owing to booming medical tourism, swiftly developing healthcare infrastructure, and growing awareness in the developing countries, namely, India, China, Singapore, and Australia.
The Middle East & Africa has the least share of the global theranostics market. In addition, the major market share of the region would be held by the Middle Eastern region due to developing healthcare system and medical infrastructure in the Arab countries.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/theranostics-market-8057
Theranostics Market HighlightsThe global theranostics market size accounted for USD 7,968.4 million in 2018 and is projected to grow at a CAGR of 11.4% over the forecast period.
Theranostics is a proposed diagnostic methodology for personalizing therapeutic intervention and the integration of imaging and therapy in a single system, enabling simultaneous therapy and follow-up of the treatment.
Some of the market growth factors are increasing development of novel companion diagnostic tests, emerging use of theranostics, increasing partnerships and collaborations by major market players to develop innovative companion diagnostics, and rising burden of chronic diseases.
In contrast, lack of proper defined regulations for theranostics tests and inadequate reimbursement facilities in most of the countries are anticipated to impede the market growth during the forecast period.Molecular theranostics is a major field which includes small biochemical moieties and biomacromolecules.
Theranostics is important for personalized as well as precision medicine that provides therapeutic outcome so that a physician can make a decision pertaining to the course of treatment for the patient.Theranostics Market SegmentationThe global theranostics market has been segmented into the therapeutic area, technology, end user, and region.By therapeutic area, the market has been segmented into oncology, cardiovascular diseases, neurological disorders, immunological disorders, and others.
The oncology segment is further categorized into breast cancer, colorectal cancer, lung cancer, cervical cancer, and others.On the basis of technology, the market has been divided into polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), sequencing, and others.
Biosensor Market Research Report: Information By Technology (Electrochemical Biosensors, Optical Biosensors, Thermal Biosensors and Piezoelectric Biosensors), By End User (Point of Care, Home Diagnostics, Research Laboratories, Food Industry and Security and Biodefense), By Application (Medical Testing, Food Toxicity, Industrial Process, Environmental and Agricultural Testing) - Forecast till 2027Biosensors are analytical devices composed of biological detecting elements like sensor system and a transducer for providing analytical information.
To recognize the function and structure of different molecules, these devices help convert the biological response into an electrical response.
When compared with any other existing diagnostic devices, the biosensors are much more advanced in terms of selectivity and sensitivity.
Its effective capability of prompt detection and measuring wide spectrum across different applications make it a highly beneficial device.
In the agricultural and food industries, its use involves the checking of ecological pollution control.
According to the in-depth research conducted by Market Research Future (MRFR), the global biosensor market is expected to grow at a moderate pace due to a number of factors.
It helps Type 1 and Type 2 diabetes patients to manage blood test results from a glucose meter, records of actual insulin delivery, statistical evaluation.The increasing prevalence of diabetes, technological advancements, rising demand for selfcare, and involvement of major players in product launch, collaboration, and strategic merger & acquisitions are the major factors driving the growth of the global digital diabetes management market.
Additionally, increasing research and development spending by the top players are fueling the growth of the market during forecast period.
Also, in 2018, Roche Diagnostics and Wellthy Therapeutics Private Limited (India) signed a partnership for offering an artificial intelligence-based digital diabetes coaching solution for users of the Accu-Chek Active system.The global digital diabetes management market is accounted for USD 4,464.8 million in 2017 and expected to register ~ 23.7 % CAGR during the forecast period (2018–2023).
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7527Global Digital Diabetes Management Market: Competitive LandscapeSome of the key players in the global digital diabetes management market areAbbott LaboratoriesAgamatrix, Inc.Ascensia Diabetes Care Holdings Ag.Braun Melsungen AGDariohealth CorporationDexcom, Inc.Hoffmann-La RocheGlooko, Inc.Insulet CorporationLifescan, Inc.Medtronic PLCTandem Diabetes Care, Inc.TidepoolDigital Diabetes Management Market SegmentationThe global digital diabetes management market has been segmented on the basis of type, product and services, end user, and region.On the basis of type, the market has been classified as wearable devices and handheld devices.
The devices have been sub- segmented into smart glucose meters, smart insulin pens, continuous glucose monitoring systems, smart insulin pumps/closed loop systems & smart insulin patches.
The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development.
It helps Type 1 and Type 2 diabetes patients to manage blood test results from a glucose meter, records of actual insulin delivery, statistical evaluation.
The increasing prevalence of diabetes, technological advancements, rising demand for selfcare, and involvement of major players in product launch, collaboration, and strategic merger & acquisitions are the major factors driving the growth of the global digital diabetes management market.
Additionally, increasing research and development spending by the top players are fueling the growth of the market during forecast period.
The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development.
Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to increasing investments in healthcare, rising number of the diabetes patient, expansions strategy by market players in the region, and favorable government initiatives for healthcare facilities.
SegmentationThe global digital diabetes management market has been segmented on the basis of type, product and services, end user, and region.On the basis of type, the market has been classified as wearable devices and handheld devices.
It helps Type 1 and Type 2 diabetes patients to manage blood test results from a glucose meter, records of actual insulin delivery, statistical evaluation.
The increasing prevalence of diabetes, technological advancements, rising demand for selfcare, and involvement of major players in product launch, collaboration, and strategic merger & acquisitions are the major factors driving the growth of the global digital diabetes management market.
Additionally, increasing research and development spending by the top players are fueling the growth of the market during forecast period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7527Regional AnalysisThe market is likely to dominate by Americas during the forecast period owing to the advancement in technology, and favorable reimbursement policies.
The European market is expected to be the second-largest due to government funding and support of the healthcare sector, coupled with increasing research and development.
Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to increasing investments in healthcare, rising number of the diabetes patient, expansions strategy by market players in the region, and favorable government initiatives for healthcare facilities.
The market in the Middle East & Africa is likely to account for the smallest share of the global digital diabetes management market.SegmentationThe global digital diabetes management market has been segmented on the basis of type, product and services, end user, and region.On the basis of type, the market has been classified as wearable devices and handheld devices.
COVID-19 Impact Analysis on Medical Biosensors Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2020-2027.
The report encompasses data regarding market share and recent developments by key players.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Medical Biosensors Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/medical-biosensors-market/download-sampleMarket DynamicsThe global medical biosensors market is projected to emerge at a robust rate during the forecast period.
Rising technology advancements in microelectronics and biotechnology, increasing market penetration of electronic medical records, growing patient awareness levels, and enhanced applications in the cardiac care and point of care segment complement market growth.
However, the pace of medical biosensors technologies adaptability is sluggish, which is curbing the global market expansion.The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis.
